Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

OXiGENE Presents Support for Cathepsin L Inhibitors

By R&D Editors | April 5, 2011

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the presentation of positive preclinical data supporting development of its novel, non-peptidic cathepsin L inhibitors as anticancer agents. The data were presented at the 102nd Annual Meeting of the American Association of Cancer Research in Orlando, Florida.

Cysteine cathepsins are a family of lysosomal proteases that are often up-regulated in a variety of cancers and that have been implicated in key processes in cancer progression. Small molecule inhibitors of the cysteine protease cathepsin L have the potential to limit degradation of extracellular matrix in the normal tissue surrounding the tumor, thus retarding cancer metastasis. It has also been established that cathepsin L is involved in blood vessel development, and thus inhibitors have the potential to suppress tumor growth and dissemination through an anti-angiogenic effect.

“The discovery of new chemotherapeutic strategies for inhibiting the growth and spread of cancer, such as our novel class of cathepsin inhibitors, represents an important achievement in the effort to enhance both cancer patient quality of life and survival. We are very encouraged by the preclinical safety and efficacy data presented at the AACR meeting with our small molecule cathepsin L inhibitors. Our goal is to advance these promising agents towards clinical evaluation,” said Dr. Dai Chaplin, OXiGENE’s Chief Scientific Officer

In a presentation titled, Abrogation of Prostate Cancer Cell Metastatic Phenotype by Cathepsin L Inhibition, Dhivya Sudhan and Professor Dietmar Siemann from The Shands Cancer Center at The University of Florida demonstrated that OXiGENE’s lead cathepsin L inhibitor, KGP94, inhibited the metastatic phenotype in the three human prostate cancer cell lines. KGP94 mediated abrogation of tumor cell migration and invasion occurred in the absence of cytotoxic effects and was a consequence of an inhibitory effect on secreted and not nuclear cathespsin-L.

Professor Siemann commented: “Our findings strongly support a mechanism of action where KGP94 affects the ability of cathepsin-L to break down extracellular matrix, which is important in invasive and angiogenic processes.”

A second presentation, titled Development and Initial Evaluation of the Antitumor Activity of a Functionalized Benzophenone Thiosemicarbazone Inhibitor of Cathepsin L, by Professors Mary Lynn Trawick and Kevin G. Pinney from Baylor University and Professor Michael Horsman from Arhus University Hospital in Denmark, demonstrated that KGP94 and other structurally related compounds inhibited the invasion and migration of DU145 prostate cancer cells through matrigel. In addition, the professors presented initial in vivo data from a mouse breast cancer model showing significant antitumor effects against both recently implanted and established tumors. These antitumor effects are consistent with a mechanism impacting tumor growth and vascularization.

Date: April 4, 2011
Source: OXiGENE, Inc. 

Related Articles Read More >

2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs
Probiotics power a bioresorbable battery that can run from 4 to 100+ minutes
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE